MannKind Corporation (MNKD)
| Market Cap | 1.08B |
| Revenue (ttm) | 65.14M |
| Net Income (ttm) | -57.24M |
| Shares Out | 222.59M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $4.03 |
| Previous Close | $4.02 |
| Change ($) | 0.01 |
| Change (%) | 0.25% |
| Day's Open | 3.97 |
| Day's Range | 3.91 - 4.22 |
| Day's Volume | 3,395,912 |
| 52-Week Range | 1.14 - 6.25 |
MannKind (NASDAQ:MNKD) announces its next round of earnings this Wednesday, May 12. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.
WESTLAKE VILLAGE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients wi...
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WESTLAKE VILLAGE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that on April 22, 2021 it and MidCap Financial Trust, as agent, entered into an amendment of th...
Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® t...
WESTLAKE VILLAGE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount o...
WESTLAKE VILLAGE, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients ...
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients ...
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Note...
An analyst is excited about the company's prospects.
WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients w...
WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 fourth quarter and full year financial results and its management will host a confere...
MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright Bioconnect 2021 Brokers Conference (Transcript)
WESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients w...
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-promotion agr...
Kent Kresa, former Chairman, will continue to serve as a Director Kent Kresa, former Chairman, will continue to serve as a Director
Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product Lead investigational product (inhaled clofazimine) designated by the F...
WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration ...
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...
MannKind Corporation (MNKD) CEO Michael Castagna on Q3 2020 Results - Earnings Call Transcript
MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and -2.48%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call to Begin Today at 5:00 PM ET
MannKind Corporation is a biopharma company focused on developing and commercializing inhaled therapeutics for endocrinology and lung diseases. Mannkind has one FDA-approved inhalable insulin formulatio...
WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to dis...
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Transcript)
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript)
MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 22nd Annual Global Investment Conference (Transcript)
MannKind Corporation's (MNKD) CEO Michael Castagna at H.C. Wainwright 2second Annual Global Investment Conference (Transcript)
WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patient...
WESTLAKE VILLAGE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Affairs and ...
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients...
MannKind Corporation's (MNKD) CEO Michael Castagna on Q2 2020 Results - Earnings Call Transcript
MannKind (MNKD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference Call to Begin Today at 5:00 PM ET Conference Call to Begin Today at 5:00 PM ET
MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020
WESTLAKE VILLAGE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to ...
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.
We will have to wait to see if the wind is truly changing to the bears, or if the bulls can come back throughout the day – either way, our deep learning algorithms paired with Artificial Intelligence (“...
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Lytham Partners Virtual Investor Growth Conference (Transcript)
Before you consider going all in on MNKD stock, consider that the company is itself going all in on one product, and that comes with risks. The post MannKind Is Crushing It, but Beware or You’ll Be Crus...
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lyt...
Momentum is still in swing from the biotech's recent presentations.
Investors liked the biotech's presentations at a major diabetes conference.
WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presente...
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyva... [Read more...]
| Industry Biotechnology | IPO Date Jul 28, 2004 |
| CEO Michael Castagna | Employees 240 |
| Stock Exchange NASDAQ | Ticker Symbol MNKD |
Financial Performance
In 2020, MNKD's revenue was $65.14 million, an increase of 3.34% compared to the previous year's $63.04 million. Losses were -$57.24 million, 10.3% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price forecast is 6.50, which is an increase of 61.29% from the latest price.